Farms.com Home   News

A Key Agricultural Manufacturer - S3 Enterprises - Has Been Sold

Bob Sonntag President and owner of S3 Enterprises has retired and sold his interests in the Swift Current based Agricultural Manufacturer to Forage Capital Partners and Roynat Equity Partners.
 
Forage Capital Partners head office is located in Calgary, Alberta while Roynat Equity Partnersis a division of Roynat Capital Inc a wholly owned subsidiary of Scotiabank
 
Steven Leakos, Managing Director of Forage Capital says they are very excited about what the future holds for S3.
 
"The thing that impressed us about S3 was its culture, its willingness to approach the market differently, and its leadership."
 
Tobin Hayward, Director at Roynat Equity Partners is pleased with the move.
 
"We look forward to expanding upon S3’s remarkable success and partnering with the S3 team as we continue to support the ongoing growth."
 
Sonntag began working in 1985 at what was then Rem Manufacturing, in 2006 he bought the company and rebranded it as S3 expanding its operations from agricultural tynes (tines), rake teeth and springs to include the Delta Harrow plant in Iowa.
 
In the last few years he's stepped back from day to day operations turning things over to CEO Richelle Andreas and the rest of the S3 Management team.
Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.